Pyratape P Horse Wormer 40% w/w Oral Paste

Země: Velká Británie

Jazyk: angličtina

Zdroj: VMD (Veterinary Medicines Directorate)

Aktivní složka:

Pyrantel Embonate

Dostupné s:

Cross Vetpharm Group Ltd

ATC kód:

QP52AF02

INN (Mezinárodní Name):

Pyrantel Embonate

Léková forma:

Oral paste

Druh předpisu:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Terapeutické skupiny:

Horses

Terapeutické oblasti:

Anthelmintic

Stav Autorizace:

Authorized

Datum autorizace:

1996-08-02

Charakteristika produktu

Revised: 11 June 2008
AN: 01659/2007
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF VETERINARY MEDICINAL PRODUCT
Pyratape P Horse Wormer
40% w/w Oral Paste
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Substance
Per Syringe
Pyrantel embonate
11.4g
Excipients
Butylated Hydroxytoluene
0.0057g
For full list of excipients, please see section 6.1.
3.
PHARMACEUTICAL FORM
Oral Paste
Pale yellow to buff coloured paste
4.
CLINICAL PARTICULARS
4.1
Target Species
Horses and ponies.
4.2
Indications for use, specifying the target species
Pyrantel embonate is a broad spectrum anthelmintic. Pyrantel embonate
is
indicated for use in the horse for the control and treatment of adult
infections of
large and small strongyles, Pinworms, Roundworms, Tapeworms.
Pyrantel embonate has a broad spectrum of activity, including activity
against:
Large strongyles:
_Stronglylus vulgaris, S. edentatus, S. equinus._
Small strongyles:
_Trichonema spp. (Cyathostomes), Triodontophorus spp._
Pinworms:
_Oxyuris equi, Probstmayria vivipara._
Large roundworms:
_Parascaris equorum._
Tape worms:
_Anoplocephala perfoliata._
Pyratape P SPC UK Page 1 of 5
Revised: 11 June 2008
AN: 01659/2007
4.3
Contra-indications
Not for use in foals less than 4 weeks of age.
Contraindicated in known sensitivity to pyrantel and in severely
debilitated
animals.
4.4
Special warnings for each target species.
Care should be taken to avoid the following practices because they
increase the
risk of development of resistence and could ultimately result in
ineffective
therapy:

Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.

Underdosing, which may be due to underestimation of weight,
misadministeration of the product, or lack of calibration of the
dosing
device(if any).
Suspected clinical cases of resistence to anthelmintics should be
further
investigated using appropriate tests (e.g. Faecal Egg Count Reduction
Test).
Where the results of the test(s) strongly suggest resistance to a
particular
anthelminitc, an anthelmi